Latest news
Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold - MarketBeatMarketBeat · Sat, 08 Aug 2026 05:48:57 GMTH.C. Wainwright Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $5 - MoomooMoomoo · Sat, 08 Aug 2026 03:45:24 GMTEditas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement - BitgetBitget · Fri, 07 Aug 2026 22:13:01 GMTEditas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000 - Stock TitanStock Titan · Fri, 07 Aug 2026 21:16:53 GMTEditas Medicine, Inc. (EDIT) director reports no share or option holdings - Stock TitanStock Titan · Fri, 07 Aug 2026 21:16:37 GMTEditas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger - simplywall.stsimplywall.st · Fri, 07 Aug 2026 04:57:04 GMTEDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 15:26:00 GMTEditas Medicine Q2 Operating Expenses USD 30. - MoomooMoomoo · Wed, 05 Aug 2026 23:31:13 GMT